Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi ditches mRNA COVID-19 vaccine after rivals' success

09/28/2021 | 08:13am EDT
FILE PHOTO: A test tube is seen in front of a displayed Sanofi logo in this illustration

PARIS (Reuters) -Sanofi is dropping plans for its own mRNA-based COVID-19 vaccine because of the dominance achieved by BioNTech-Pfizer and Moderna in using the technology to fight the pandemic, the company said on Tuesday.

The move highlights the challenges of competing in particular with pioneer BioNTech, which rose from obscurity through its alliance with pharma major Pfizer last year. They have delivered close to 1.5 billion doses so far to become the Western world's largest COVID-19 vaccine maker.

French healthcare group Sanofi will instead focus on efforts with British partner GlaxoSmithKline to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach, where mass trials are ongoing.

The decision to drop clinical development of a shot based on mRNA, or messenger RNA, acquired as part of its takeover of Translate Bio, came despite positive Phase I/II study interim results https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-28-08-00-00-2304069 announced on Tuesday, where participants' blood readings showed a strong immune reaction.

But Sanofi said the read-out encouraged it only to pursue the technology as a potential vaccine against influenza and other diseases, giving up on the area of COVID-19 because of the strong market presence of the two approved mRNA shots.

"The results are extremely important as they show us that the platform we acquired works," Thomas Triomphe, head of the Sanofi Pasteur vaccines division, told journalists. He said kicking off final Phase III trials now made no sense.

"Would it, responsibly, be the best use of this wealth of science afforded by mRNA vaccines to make a COVID-19 vaccine and try and bring another mRNA COVID-19 vaccine to people who already today may not want an mRNA COVID-19 vaccine? Clearly not," Triomphe said.

He also dismissed the prospect for annual repeat shots, which has been intensely debated by researchers and pharmaceutical executives, with clear trial results on the need for yearly boosters still to come.

U.S. regulators cleared a third Pfizer-BioNTech shot half a year after the initial two-shot course for some at-risk groups and Moderna aims to follow suit.

Triomphe said that given evidence of virus-fighting antibodies surging after a third shot, a recurring market was out of the question. "With a fourth dose you'd have extremely high antibodies and you absolutely would not need an annual COVID-19 vaccine." he added.

He said that by May or June 2022, some 24 billion doses of COVID-19 jabs made by different manufacturers would already have been delivered.

Sanofi's shares were 0.1% higher 82.2 euros by 1136 GMT, outperforming a 1.21% decline in the STOXX Europe 600 Health Care.

"The decision to end RNA looks to be interpreted as positive since they will save development costs and concentrate on other products and ventures," said Ion-Marc Valahu, a fund manager at Geneva-based investment firm Clairinvest.

But Sanofi's comparatively slow progress in developing a COVID-19 vaccine - its project with GSK was delayed late last year - has been a blow to its prestige and lamented by some French politicians.

The company said it started testing an mRNA shot against seasonal influenza in humans in June and would launch follow-on clinical studies next year.


The development of RNA flu shots is already shaping up to be a tight race as drugmakers hope they can more quickly adjust the vaccine to ever-changing strains in circulation. Unlike the highly mutant flu virus, the coronavirus reduces genetic copying errors when replicating in a host organism.

Pfizer said this week it had started testing an mRNA flu vaccine. Moderna has several influenza vaccine candidates in development, including combinations that include a COVID-19 booster.

Established influenza vaccine supplier Seqirus, part of Australia's CSL, for instance, is working on next-generation low-dose RNA flu shots, known as self-amplifying RNA.

Companies including Novavax are also working on novel flu shots using new technology beyond mRNA.

Sanofi reported 2.5 billion euros ($2.9 billion) in sales from flu vaccines in 2020, the largest of its vaccine business, which recorded total sales of 5.9 billion euros.

The mRNA COVID-19 vaccines trick the human body into producing proteins known as antigens that are found on the surface of the coronavirus that causes the disease. That primes the immune system to quell future infections.

Under the more traditional protein-based vaccine approach that Sanofi will now focus on, the antigen is bioengineered in labs and combined with an efficacy-boosting ingredient known as an adjuvant, provided by GSK.

Triomphe said the European Union and Britain had ordered 75 million doses of this vaccine, banking on future regulatory approval.

German biotech firm CureVac earlier this month also acknowledged rivals' dominance when it cancelled some of the contract manufacturing deals for its experimental mRNA COVID-19 vaccine with two prospective partners.

CureVac's product is under review by the EU's drugs regulator, with an uncertain outcome after disappointing trial results.

($1 = 0.8537 euros)

(Reporting by Ludwig Burger in Frankfurt, Sarah White and Sudip Kar-Gupta in ParisEditing by Louise Heavens and Mark Potter)

By Sarah White and Ludwig Burger

© Reuters 2021
All news about SANOFI
10/15SANOFI : New long-term data reinforcing promising safety and efficacy profile of brain-pen..
10/14SANOFI : Goldman Sachs keeps its Buy rating
10/14SANOFI : JP Morgan keeps its Buy rating
10/13SANOFI : Update from Sanofi regarding Kevzara (sarilumab) - Supply constraints anticipated..
10/13SANOFI : Says Multiple Sclerosis Drug Well-Tolerated at One-Year Mark of Phase 2b Extensio..
10/13SANOFI : Multiple Sclerosis Drug Remains Tolerable After One Year In Extension Study
10/13SANOFI : New long-term data reinforcing promising safety and efficacy profile of brain-pen..
10/13SANOFI : Expects Rheumatoid Arthritis Drug Supply To Remain Constrained Until 2022
10/13NHTHERAGUIX : NH TherAguix reporte son projet d'introduction en bourse sur le marché Euron..
10/12SANOFI : Warns of Kevzara Supply Constraints Until Early 2022
More news
Analyst Recommendations on SANOFI
More recommendations
Sales 2021 37 358 M 43 491 M 43 491 M
Net income 2021 6 037 M 7 029 M 7 029 M
Net Debt 2021 8 894 M 10 354 M 10 354 M
P/E ratio 2021 17,2x
Yield 2021 3,99%
Capitalization 104 B 121 B 121 B
EV / Sales 2021 3,01x
EV / Sales 2022 2,75x
Nbr of Employees 99 412
Free-Float 88,4%
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 82,63 €
Average target price 104,90 €
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI5.03%120 395
JOHNSON & JOHNSON1.74%421 513
ROCHE HOLDING AG17.78%342 644
NOVO NORDISK A/S56.38%238 110
PFIZER, INC.12.71%231 668